Premium
IgM myeloma: A multicenter retrospective study of 134 patients
Author(s) -
Castillo Jorge J.,
Jurczyszyn Artur,
Brozova Lucie,
Crusoe Edvan,
Czepiel Jacek,
Davila Julio,
Dispenzieri Angela,
Eveillard Marion,
Fiala Mark A.,
Ghobrial Irene M.,
Gozzetti Alessandro,
Gustine Joshua N.,
Hajek Roman,
Hungria Vania,
Jarkovsky Jiri,
Jayabalan David,
Laubach Jacob P.,
Lewicka Barbara,
Maisnar Vladimir,
Manasanch Elisabet E.,
Moreau Philippe,
Morgan Elizabeth A.,
Nahi Hareth,
Niesvizky Ruben,
PabaPrada Claudia,
Pika Tomas,
Pour Ludek,
Reagan John L.,
Richardson Paul G.,
Shah Jatin,
Spicka Ivan,
Vij Ravi,
WaszczukGajda Anna,
Gertz Morie A.
Publication year - 2017
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24753
Subject(s) - medicine , multiple myeloma , gastroenterology , bone marrow , anemia , monoclonal , malignancy , retrospective cohort study , hematology , immunology , monoclonal antibody , antibody
IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL −1 with 19% of patients presenting with levels >6,000 mg dL −1 . International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t (11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival ( P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.